Photo taken on Nov. 7, 2019 shows the booth of Pfizer Inc. during the second China International Import Expo (CIIE) in Shanghai, east China. (Xinhua/Fan Peishen)
Depending on current infection rates, a conclusive readout on efficacy of the vaccine candidate is expected by the end of next month.
WASHINGTON, Sept. 16 (Xinhua) -- Participants of a phase 3 clinical trial of American biopharmaceutical company Pfizer's COVID-19 vaccine candidate were experiencing mild-to-moderate side effects, said the company on Tuesday.
In a presentation to investors, Pfizer said side effects included fatigue, headache, chills and muscle pain. Some participants in the trial also developed fevers, including a few high fevers.
The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine, BNT162b2, that Pfizer is developing with German partner BioNTech.
Over 12,000 study participants had received a second dose of the vaccine, Pfizer executives said on an investor conference call.
Depending on current infection rates, a conclusive readout on efficacy of the vaccine candidate is expected by the end of next month, according to the company.
Photo taken on May 18, 2020 shows a logo in front of AstraZeneca's building in Luton, Britain. (Photo by Tim Ireland/Xinhua)
The latest comments by Pfizer came after multinational pharmaceutical company AstraZeneca's COVID-19 vaccine trials were put on hold globally on Sept. 6 following a report of serious side effect in a volunteer in Britain.
AstraZeneca's trials resumed in Britain and Brazil on Monday following the green light from British regulators, but remain on hold in the United States, according to a report of Fox Business. ■
